$Eyenovia Inc(EYEN.US)$Eyenovia (NASDAQ:EYEN) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.17) by 35.29 percent. This is a 53.33 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $4.993 thousand which missed the analyst consensus estimate of $816.667 thousand by 99.39 percent.
$Eyenovia Inc(EYEN.US)$Reuters· just Eyenovia Inc - Requested Meeting With FDA to Discuss Validation of the Gen-2 Dispenser, Which We Anticipate Will Occur This Summer
$Eyenovia Inc(EYEN.US)$Well im taking this for a earnings spin! Hehehe! Wish me luck! I know that next Q will probably be much better because of some things not yet settled? But i really like it and if my earnings spin crashes? Well no harm because ive traded it before and i like it! So ill just swing it! Hehehe! NFA
$Eyenovia Inc(EYEN.US)$Ok i will make you a deal! If you break 1.00? Whether that be today or soon. I will buy more! Even if i sell my whole position, ill buy right back at a buck! I mean thats a pretty good deal for you? Hehehe
$Eyenovia Inc(EYEN.US)$Eyenovia Provides Clinical and Scientific Update On FDA-Approved Products Mydcombi And Clobetasol Propionate Ophthalmic Suspension Benzinga· 1 min ago Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8μL spray per eye) Also announces upcoming ARVO presentation on the unique technology behind clobetasol that allows for future ophthalmic suspensions to be dispensed with the O...
$Eyenovia Inc(EYEN.US)$Hehehe! Company entered into a purchase agreement with a “ Fundementals-Based Healthcare Investor “by selling 3,223,726 shares at .6204! Yes they are using the money to complete the CHAPERONE PEDIATRIC MYOPIA Clinical Study! But how at that price does it increase shareholder value? Well at least in the short term it hurts! Study does great? Yes it will help! But .91 down to .57! ...
2
報告
Jaguar8 :
Maybe they see “increasing shareholder value” differently. They have an insider definition
$Eyenovia Inc(EYEN.US)$Eyenovia Initiates Process To Explore Strategic Alternatives To Maximize Shareholder Value Benzinga· 5 mins ago The company announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia (MicroPine). In conjunction with the strategic process and focus on its late stage MicroPine asset, Eyenovia reiterated its immediate commercialization opportunities and corporate savings intended to reduce operating expen...
Eyenovia Incに関するコメント
Eyenovia Inc - Requested Meeting With FDA to Discuss Validation of the Gen-2 Dispenser, Which We Anticipate Will Occur This Summer
Benzinga· 1 min ago
Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8μL spray per eye)
Also announces upcoming ARVO presentation on the unique technology behind clobetasol that allows for future ophthalmic suspensions to be dispensed with the O...
Benzinga· 5 mins ago
The company announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia (MicroPine). In conjunction with the strategic process and focus on its late stage MicroPine asset, Eyenovia reiterated its immediate commercialization opportunities and corporate savings intended to reduce operating expen...
まだコメントはありません